AbbVie Inc.
AbbVie to Showcase Multiple Myeloma Data and Aesthetics Updates
·Consolidated from 3 sources
AbbVie is set to present new data on its multiple myeloma treatments, including Phase 3 results for Etentamig, at the upcoming International Myeloma Society meeting. Separately, its Allergan Aesthetics division is sharing clinical findings related to skin quality improvements in patients using medical weight loss drugs.
AbbVie Inc. is preparing to share significant clinical trial results and portfolio updates with the medical community. The company announced it will present Phase 3 data for its multiple myeloma drug, Etentamig, at the 2026 International Myeloma Society (IMS) meeting. This presentation is part of a broader showcase of AbbVie's extensive work in the multiple myeloma space.
Coverage today also highlights potential future considerations for AbbVie's stock performance, particularly concerning the growth trajectory of its blockbuster drug SKYRIZI. Analysts are reportedly examining scenarios where the drug's growth might moderate, and what the implications could be for the company's overall financial outlook.
In parallel, AbbVie's Allergan Aesthetics segment is contributing new clinical insights. Reports indicate that Allergan Aesthetics will present data evaluating improvements in skin quality among individuals who are undergoing treatment with medical weight loss medications. These findings aim to shed light on the dermatological effects associated with these popular therapeutic agents.
Sources
This recap was generated by consolidating the public headlines below.
- AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) MeetingSep 17, 2026
- What Happens To AbbVie Stock If SKYRIZI Slows Down?Sep 17, 2026
- Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss MedicationsSep 17, 2026